Robert Ross
President at SURFACE ONCOLOGY, INC.
Net worth: - $ as of 30/04/2024
Robert Ross active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SURFACE ONCOLOGY, INC. | President | - | - |
| Director/Board Member | 01/04/2021 | - | |
| Chief Executive Officer | 01/04/2021 | - | |
| Chief Tech/Sci/R&D Officer | 01/10/2016 | 01/04/2021 | |
| XILIO THERAPEUTICS, INC. | Director/Board Member | 16/06/2022 | - |
| Independent Dir/Board Member | 16/06/2022 | - | |
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Director/Board Member | 03/09/2020 | - |
Career history of Robert Ross
Former positions of Robert Ross
| Companies | Position | Start | End |
|---|---|---|---|
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01/10/2012 | 01/10/2016 |
Training of Robert Ross
| Stanford University | Undergraduate Degree |
| Harvard Medical School | Graduate Degree |
| Columbia University College of Physicians & Surgeons | Graduate Degree |
Statistics
International
| United States | 8 |
Operational
| Director/Board Member | 3 |
| Graduate Degree | 2 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| XILIO THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Robert Ross
- Experience
